Coherus Oncology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.8%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$73Mnext fiscal year
FY EPS (est.)
-$0.75next fiscal year
Monitoring Framework
Key Performance Indicators
LOQTORZI (toripalimab-tpzi) Net Product Revenue Quarterly11.8MTarget: 15000000 per quarter in 2026, 30000000 to 35000000 per quarter in 2027, and 175000000 annualized run rate by 2028
Cash, Cash Equivalents, and Marketable Securities Quarterly167MTarget: Sufficient liquidity to fund operations through key 2026 clinical readouts
Watch Items
- Casdozokitug (IL-27 antagonist) Phase 2 clinical trial readout in first-line hepatocellular carcinoma (uHCC)Trigger: Initial data readout expected around mid-2026Action: Evaluate efficacy (ORR, PFS) and safety of the triplet combination (casdozokitug + toripalimab + bevacizumab) to determine phase 3 advancement or partnership potential.
- Tagmokitug (formerly CHS-114, anti-CCR8 antibody) Phase 1b clinical trial readoutsTrigger: Initial data readouts in head and neck squamous cell carcinoma (HNSCC) and gastric cancer expected in mid-2026Action: Assess selective intratumoral Treg depletion and translational biomarker data to validate best-in-class potential.
Research as of 20 Jun 2026